<div><span style="font-family: georgia, palatino, serif; font-size: 12pt;">The global HIV treatment market across seven major markets is projected to grow from $26.5 billion in 2023 to $32.1 billion by 2033, reflecting a compound annual growth rate (CAGR) of 1.9%, according to a report by GlobalData.</span></div>
<div>&nbsp;</div>
<div><span style="font-family: georgia, palatino, serif; font-size: 12pt;">This growth is primarily attributed to the increased adoption of long-acting injectable therapies and the anticipated introduction of novel single-tablet regimens (STRs). The report indicates a shift from traditional three-drug STRs to two-drug combinations, aiming to reduce toxicity and side effects.</span></div>
<div>&nbsp;</div>
<div><span style="font-family: georgia, palatino, serif; font-size: 12pt;">Six products are currently in Phase III development and are expected to launch by 2033, including four two-drug STRs:</span></div>
<div>&nbsp;</div>
<div><span style="font-family: georgia, palatino, serif; font-size: 12pt;">Gilead Sciences' once-daily combination of bictegravir and lenacapavir</span></div>
<div>&nbsp;</div>
<div><span style="font-family: georgia, palatino, serif; font-size: 12pt;">Merck's once-daily doravirine and islatravir</span></div>
<div>&nbsp;</div>
<div><span style="font-family: georgia, palatino, serif; font-size: 12pt;">Gilead's once-weekly islatravir and lenacapavir</span></div>
<div>&nbsp;</div>
<div><span style="font-family: georgia, palatino, serif; font-size: 12pt;">A once-weekly regimen of GS-1720 and GS-4182, developed jointly by Gilead and Merck</span></div>
<div>&nbsp;</div>
<div><span style="font-family: georgia, palatino, serif; font-size: 12pt;">These new regimens aim to provide more convenient options for patients, moving away from the current daily administration requirement.</span></div>
<div>&nbsp;</div>
<div><span style="font-family: georgia, palatino, serif; font-size: 12pt;">Other notable therapies in late-stage development include CytoDyn's once-weekly leronlimab, intended for patients with CCR5-type virus, and Gilead's biannual injectable lenacapavir for pre-exposure prophylaxis (PrEP).</span></div>
<div>&nbsp;</div>
<div><span style="font-family: georgia, palatino, serif; font-size: 12pt;">Long-acting injectable therapies are expected to gain significant market share due to their infrequent dosing schedules, enhancing patient convenience. For instance, lenacapavir is initially anticipated to be administered subcutaneously every six months for PrEP, with ongoing clinical trials exploring its efficacy when administered once a year. Phase I trial data has demonstrated lenacapavir's potential when administered intramuscularly on an annual basis.</span></div>
<div>&nbsp;</div>
<div><span style="font-family: georgia, palatino, serif; font-size: 12pt;">Subcutaneous lenacapavir has shown 100% efficacy in preventing new HIV infections, highlighting its promise as a significant tool for PrEP. However, its higher cost compared to daily oral PrEP may pose accessibility challenges, as noted by key opinion leaders interviewed by GlobalData.</span></div>

Advancements in long-acting injectable therapies and two-drug regimens drive steady growth in HIV treatment landscape

Global HIV Market Projected to Surpass $32 Billion Across Seven Major Markets by 2033

Advancements in long-acting injectable therapies and two-drug regimens drive steady growth in HIV treatment landscape

May 12, 2025 | 09:57 IST